anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Multiple target-organ damages (TODs) in the same patient are common and further increase the risk of cardiovascular disease. However, the relationship between ambulatory central systolic blood pressure (SBP) and multiple TODs has yet to be explored.
METHODS AND RESULTS: MobilO-Graph PWA was used to monitor the participants' ambulatory blood pressure, and the presence of left ventricular hypertrophy, carotid hypertrophy, and kidney injury were used to define TOD. Logistic regression analyses and receiver operating characteristic analyses were used to explore the correlation between SBP and TOD. Overall, 2018 nondialysis patients with chronic kidney disease were included and 580 (28.74%) had multiple TODs. Twenty-four-hour central SBP with c2 calibration exhibited a stronger correlation with the increasing number of TOD compared with 24-hour brachial SBP in ordinal logistic regression analyses. In the multivariable analyses with the presence of multiple TODs, the odds ratios were 1.786 (95% CI, 1.474-2.165; P<0.001) for 24-hour brachial SBP and 1.949 (95% CI, 1.605-2.366; P<0.001) for 24-hour central SBP with c2 calibration. The receiver operating characteristic analyses also showed that 24-hour central SBP with c2 calibration had higher discrimination than 24-hour brachial SBP regarding multiple TODs (P<0.001). In addition, using 130/135 mm Hg as the threshold for 24-hour brachial SBP/central SBP with c2 calibration to cross-classify, the prevalence of multiple TODs was greater in cases of concordant hypertension compared with cases of isolated brachial hypertension and concordant normotension, with no difference between the latter 2 conditions.
CONCLUSIONS: Twenty-four-hour central SBP with c2 calibration was more associated with the presence of multiple TODs compared with 24-hour brachial SBP and was helpful in risk classification of multiple TODs among nondialysis patients with chronic kidney disease.
The invention provides a solid compound preparation containing metformin hydrochloride and glimepiride. The solid compound preparation is prepared from metformin hydrochloride granules and glimepiride granules. The metformin hydrochloride granules contain metformin hydrochloride and an adhesive, and the glimepiride granules contain glimepiride, a water soluble filler, a disintegrating agent and an adhesive. The solid compound preparation does not contain water insoluble filler. The invention also provides a preparation method and application of the solid compound preparation. Compared with common preparations and preparations adopting a water insoluble filler, the solid compound preparation provided by the invention can significantly improve the dissolution rate of glimepiride, and can effectively reduce interaction of the two main drugs, thereby reducing the increase of related impurities in a placement process. The product has stable quality and good uniformity, so that the effectiveness and safety of drug use by patients can be improved.
In recent years, international media and the scientific community have expressed concerns regarding rising kidney health-related risks among Nepalese labour migrants in Gulf countries and Malaysia. Previous studies have highlighted poor lifestyles and work conditions among Nepalese migrants, which could potentially impact their kidney health. This qualitative study aims to explore the lifestyles and work environment of returnee Nepalese migrants who were diagnosed with kidney health problems. In-depth interviews were carried out with twelve returnee migrants, all males, with half having worked abroad for at least a decade. Our analysis yielded seven themes: (a) living and lifestyles; (b) work environment; (c) exposure to pollutants; (d) Chronic Kidney Disease (CKD) experience; (e) use of painkillers and healthcare; (f) medical expenses for CKD patients; and (g) pre-departure training. This study indicates that Nepalese migrants face numerous challenges, including limited access to clean water and sanitation facilities, poor diets, exposure to occupational hazards, and overuse of pain medication, all of which may contribute to an increased risk of kidney disease. An enhanced pre-departure and on-arrival orientation programme focusing on kidney health-related topics, including the necessary advocacy at the country of destination to provide access to basic services, may encourage migrants to adopt healthy lifestyles and safe working environments, as well as help sensitise migrants to their kidney health risks.
PURPOSE: A cosmetic composition for deodorization containing Schizandra chinensis extract is provided to effectively suppress isovaleric acid generation and to prevent side effect. CONSTITUTION: A cosmetic composition for deodorization contains Schizandra chinensis extract as an active ingredient. The cosmetic composition further contains Astragalus membranaceus or Triticum aestivum extract as an active ingredient. The extract is prepared using water or alcohol of C1-5. The cosmetic composition further contains Mentha piperita essential oil. The cosmetic composition is deodorant.
The present invention is directed to several Tofacitinib salts including Tofacitinib mono-tartrate salt, Tofacitinib mono-malate salt and Tofacitinib mono-oxalate salt. These Tofacitinib salts can be in amorphous form. The invention is also directed toward a pharmaceutical composition comprising one or more of the Tofacitinib salts, and a process for preparing the composition. The Tofacitinib salts can be used to prepare Tofacitinib mono-citrate salt. Another aspect of the invention is a process for preparing Tofacitinib mono-citrate. The Tofacitinib salts of the invention are also useful as medicaments and in methods of treating patients suffering from cancer.
Dietary supplement (Uji) This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
The invention relates to a pitavastatin calcium tablet pharmaceutical composition and a dry or wet preparation method thereof. Specifically, one aspect of the invention relates to pitavastatin calcium tablets, which comprise a tablet core and a coating layer, wherein the tablet core comprises: 1 part of pitavastatin calcium, 40-120 parts of filling agent, 4-20 parts of disintegrating agent, 0.5-5 parts of adhesive, 0.5-5 parts of stabilizer and 0.3-3 parts of lubricant. The tablet core can be lactose, microcrystalline cellulose, tricalcium phosphate, low-substituted hydroxypropyl cellulose, crospovidone, sodium carboxymethyl starch, magnesium aluminum silicate, magnesium aluminum metasilicate, hydroxypropyl methylcellulose, magnesium stearate, etc., and their combination. The tablet core can be prepared by a dry granulation tabletting or wet granulation tabletting process. Also relates to a preparation method of the pitavastatin calcium tablet and application of the pitavastatin calcium tablet in preparing a medicine for treating and/or preventing hypercholesterolemia or familial hypercholesterolemia. The tablet pharmaceutical composition has excellent properties as described in the specification.
The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
The main purpose of this proposal is to build a multicenter de-identification adult intensive care units database in Taiwan. In future, the Joint Data Management Committee and investigators can use the data for evaluation of outcome of critical care, evaluation of medical resource, quality improvement, annual report, education and training, and critical care research.

Center of Outcome and Resource Evaluation (CORE) Adult Patient Database of Australian and New Zealand Intensive Care Society (ANZICS) was founded in 1992. More than 160 intensive care units in Australia and New Zealand contribute the data into this database. This database provides medical information to Australia and New Zealand government for critical care policy making and quality improvement. The primary aim of this proposal is to build a multicenter de-identification adult intensive care units database by mutual collaboration of multiple hospitals in Taiwan. This database will include the de-identification data accruing to the regulation of Health Insurance Portability and Accountability Act (HIPAA) of United States of America from each hospital. The data can be used to help the government and critical care societies evaluate the clinical outcomes of critical care. Furthermore, this data can help to effectively allocate the medical resource, improve quality, conduct multicenter registry-based clinical research, and publish high quality research. Hope to assist Taiwan and the world to improve critical care quality.

The Taiwan Society of Critical Care Medicine, Taiwan Society of Emergency and Critical Care Medicine, and National Taiwan University Hospital invite multiple hospitals to build the multicenter de-identification adult intensive care units database. This database includes only de-identification data. A Joint Data Management Committee will be organized and be in charge of data management. The data will be used for evaluation of outcome of critical care, evaluation of medical resource, quality improvement, and publication of mutual collaboration of critical care research in research ethic committee approved research filed.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to omeprazol form B sodium salt that can be used as an inhibitor of proton pump, i. e. it shows efficiency in inhibition of gastric acid secretion. Invention describes omeprazol form B sodium salt that shows thermodynamic stability and diffraction of X-ray picture given in the description. Invention discloses also methods of preparing omeprazol form B sodium salt and the pharmaceutical preparation comprising omeprazol form B sodium salt. EFFECT: improved method of preparing. 12 cl, 8 dwg, 4 tbl
The invention relates to a method for processing Chinese medicinal materials, particularly to a method for processing scorpions. The prior method for processing the scorpions is carried out by boiling, thereby inducing the live scorpions to secrete scorpion venom to the exterior after suffering from heat flash stimulation, and the scorpion venom is thermolabile and soluble in water, so as to lose a large amount of effective ingredients at the beginning of the processing. The invention provides a novel method for processing the scorpions, which comprises the following steps of soaking a live scorpion in clean water so as to cause the scorpion to discharge food and residues in digestive tract out of the body under a comfortable environment, and killing scorpion by refrigerating at low temperature so as not to loss effective ingredients in the scorpion. The method can maximally retain the effective ingredients of the scorpion. The obtained scorpion by the method has the peptide and protein extraction amount of 1.6-2.0g/3g scorpion, and extraction rate of 53.3-66.6%, which is increased by a factor of two compared with the prior process. The inventive processing method has the advantages of improved therapeutic effect of scorpion, reduced consumption of raw materials, and increased benefit.
Arm 2. CTX PLUS HAART. HAART will be given as above. In addition, CTX will be administered at 2 weekly intervals in the Oncology Dept at KEH VIII Hospital and will consist of:- Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
We will recruit 30 patients with progressive visual function loss, due to Normal tension glaucoma (NTG) or chronic open angle glaucoma (COAG), despite optimal conventional or intraocular pressure reducing surgery treatment so far. We will proceed with an optic nerve sheath fenestration (ONSF) (according to the studies in the literature, e.g. Wax MB, Barrett DA, Hart WM Jr, Custer PL. Optic nerve sheath decompression for glaucomatous optic neuropathy with normal intraocular pressure. Arch Ophthalmol. 1993;111(9):1219-28.) and compare the cerebrospinal fluid (CSF) taken from the subarachnoid space (SAS) of the optic nerve (ON) with the CSF taken during a lumbar puncture, on the same day. Concentrations of neurobioactive substances will especially be studied. Visual acuity and visual field development before and after ONSF will be studied. Quality of life assessment will be done before and several times after ONSF.
Patients with a confirmed diagnosis of COPD based on clinical history, obstructive spirometry (FEV1/VC ratio \<70%) and radiology (e.g. hyperexpansion on plain chest radiograph; evidence of small airways disease or emphysema on cross-sectional imaging).
PURPOSE: In patients with chronic kidney disease (CKD), renal osteodystrophy may be associated with a progressive bone mass loss that increases fracture risk. Denosumab, a monoclonal antibody inhibiting osteoclast activity, is an antiresorptive medication used for the treatment osteoporosis.
METHODS: Its efficacy and safety were initially established in the FREEDOM study, showing a significant reduction in incident fractures in osteoporotic women treated with denosumab. Subsequent post hoc analyses showed its efficacy in patients stratified by kidney function, but these analyses did not include patients with advanced stages of CKD. The capability of denosumab in improving bone mineral density in uremic patients was evaluated in 12 studies including 461 dialysis patients with low bone mineral density. The improvement of bone mineral density was the final end point in these studies assessed during a follow-up of 6-60 months. Nine of these studies did not have hyperparathyroidism among criteria for patient inclusion and their participants may have low-turnover bone disease. Despite current recommendations, no patients underwent bone biopsy before denosumab therapy.
RESULTS: Overall, findings in these studies suggest that denosumab is a viable option for promoting bone mass recovery in patients with advanced stages of CKD having either high or low serum levels of PTH. However, the increase of bone mineral density was lower in patients with low serum markers of bone turnover at baseline. These studies also highlighted the need for calcium and vitamin D supplementation to prevent hypocalcemia that remains a serious concern.
CONCLUSIONS: Denosumab emerges as a potentially safe and effective option for enhancing bone health in CKD patients.
Particularly, controls will be identified retrospectively at the same hospitals based on matching of demographics, underlying diseases and duration of hospital stay (i.e. one control per case, both in the same hospital). Moreover, the mere suspicion of SARS-CoV-2-infection on admission in the ED is sufficient for enrolment. A considerable portion of these patients are actually not infected and serve as internal control.
This is a single-center, randomized, controlled, double-blind study in Chinese heart failure participants with ICD implantation. This trial aims to investigate the effect of dapagliflozin on ventricular arrhythmias in participants with HFrEF. This trial includes a screening period, a treatment period and a follow-up period. Total duration of each subject's participation in the trial is approximately 1 year. During the screening period, 120 participants with HFrEF with ICD implanted in the investigator's department were recruited. The participants should sign the informed consent and be randomly divided into 2 groups. All participants will receive the best anti-heart failure treatment for 6 months before enrollment, including ACEI/ARB/ARNI, β-blockers, spironolactone, diuretics, and digitalis. One group was randomized to receive dapagliflozin (10 mg qd) and another group received place. Participants were then enrolled in a 1-year clinical trial and investigators will record the participants' QT interval, QTc interval, frequency and mode of ICD electrical therapy, cardiac function, symptoms, signs and other indicators before and after treatment to evaluate the occurrence of ventricular arrhythmia.
BACKGROUND: Airway injuries are reported among preterm infants with bronchopulmonary dysplasia. We hypothesized that prolonged ventilation in preterm infants is associated with subglottic dilatation that can be reliably evaluated by point of care ultrasonography (POCUS).
METHODS: All preterm infants (<29-weeks) admitted to the neonatal ICU at the Advent-Health from January-2020 to June-2022 were eligible if they required invasive ventilation for ≤7 days in the first 28 days of life (control) or remained intubated for ≥28 days (prolonged ventilation). Sonography was performed by one technician and all images were reviewed by the pediatric radiologist. The trachea size was measured 3 times by randomly selecting three images. The first 20 scans were also independently reported by a different pediatric radiologist. Intra and inter-observer variability was estimated. Mean trachea size and weight at the time of imaging were compared.
RESULTS: Out of 417 eligible infants; 11 died before 28 days and 163 required ventilation for 8-27 days. Consent missed for 80 infants during COVID-19 pandemic. We enrolled 23 and 28 infants in the control & prolonged ventilation groups, respectively. Inter and intra-observer correlations were 0.83 and 0.97 respectively. Infants in the control group had higher gestation and birth weight. Infants on prolonged ventilation were at higher risk for infections, BPD, longer hospital stay and significant subglottic dilation (4.51 ± 0.04 vs 4.17 ± 0.02 mm, p < 0.01) despite smaller body weight at the time of imaging (884 ± 102 vs 1059 ± 123g, p < 0.01).
CONCLUSION: Extremely preterm infants on prolonged ventilation are at risk for sub-glottic dilatation that can be reliably measured by POCUS.
In a study addressing the high risk of chronic diseases in people with diabetes and obesity linked to metabolic syndrome, the impact of a Golden Berry diet was investigated using a diabetic animal model. Obese rats with diabetic characteristics were fed a diet containing five percent Golden Berry for 16 days. This study focused on various parameters including organ weights, expression of metabolic genes, and urinary biomarkers. Post-Golden Berry intake, there was a notable decrease in the body, liver, pancreas, visceral, and subcutaneous adipose tissue weights in these obese, hyperglycemic rats. In contrast, an increase in brown adipose tissue (BAT) cell mass was observed. This diet also resulted in reduced blood glucose levels and normalized plasma biochemical profiles, including cholesterol, triglycerides, LDL, and HDL levels. Additionally, it modulated specific urinary biomarkers, particularly pipe-colic acid, a primary marker for type 2 diabetes. Bioinformatics analysis linked these dietary effects to improved insulin signaling and adipogenesis. Regular consumption of Golden Berry effectively prevented insulin resistance and obesity in rats, underscoring its significant health benefits and the protective role of an antioxidant-rich diet against metabolic syndrome. These findings offer promising insights for future therapeutic strategies to manage and prevent obesity and related chronic diseases.
The invention relates to acrylate polymers comprising a K-value ranging from 10 to 60, which can be obtained by the radical polymerization of: 30 to 99 wt.  % of tert-butyl acrylate and/or tert-butyl methacrylate designated as monomer A; 1 to 28 wt. % of acrylic acid and/or methacrylic acid designated as monomer B, and; 0 to 60 wt. % of a radically copolymerizable monomer or of a radically copolymerizable monomer mixture designated as monomer C, whereby at least one of monomers C yields a homopolymer with a glass-transition temperature lower than 30 ~C, with the provision that the wt. %'s total 100. The radical polymerization is carried out in the presence of alkane thiols with a C chain length of C 14 to C 22. The invention also relates to acrylate polymers comprising a K-value ranging from 10 to 60, which can be obtained by the radical polymerization of: 30 to 99 wt. % of tert-butyl acrylate and/or tert-butyl methacrylate designated as monomer A; 1 to 28 wt. % of acrylic acid and/or methacrylic acid designated as monomer B, and; 0 to 60 wt. % of a radically copolymerizable monomer or of a radically copolymerizable monomer mixture designated as monomer C, whereby at least one of monomers C yields a homopolymer with a glass-transition temperature lower than 30 ~C, with the provision that the wt. %'s total 100. The radical polymerization is carried out in the presence of alkane thiols with a C chain length of C 10 to C 22 followed by a hydrogen peroxide treatment. The invention also relates to the use of these acrylate polymers as film formers as well as to their use in cosmetic preparations.
Athletic performance monitoring and tracking may provide multiple ways in which to track athletic movement and activity. Workouts may also be tagged with various parameters including mood, weather, terrain, athletic equipment, friends used and the like. Workout information may be shared to social messaging and networking outlets. Workout information shared may include map information including images of maps, interactive maps, links to maps, route information and the like and/or combinations thereof. Additionally or alternatively, an application may be configured to execute within a context of a social networking system to facilitate athletic activity data transfer and generation of workout entries in the social networking site. Recommended activities to be performed or a recommended time to perform an activity may be determined based on a user's schedule, weather or conditions forecasts, or a location of the user or the potential activity.